HM Payson & Co. Trims Stock Holdings in Novo Nordisk A/S $NVO

HM Payson & Co. cut its holdings in shares of Novo Nordisk A/S (NYSE:NVO) by 99.3% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 2,518 shares of the company’s stock after selling 346,003 shares during the period. HM Payson & Co.’s holdings in Novo Nordisk A/S were worth $140,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently bought and sold shares of the business. NewSquare Capital LLC increased its stake in Novo Nordisk A/S by 174.1% in the second quarter. NewSquare Capital LLC now owns 444 shares of the company’s stock valued at $31,000 after purchasing an additional 282 shares during the period. Mid American Wealth Advisory Group Inc. purchased a new position in shares of Novo Nordisk A/S during the second quarter worth about $37,000. State of Wyoming acquired a new position in Novo Nordisk A/S in the 1st quarter valued at about $38,000. Maseco LLP purchased a new stake in Novo Nordisk A/S during the 2nd quarter valued at approximately $39,000. Finally, Copeland Capital Management LLC lifted its position in Novo Nordisk A/S by 47.3% during the 2nd quarter. Copeland Capital Management LLC now owns 579 shares of the company’s stock worth $40,000 after acquiring an additional 186 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Trending Headlines about Novo Nordisk A/S

Here are the key news stories impacting Novo Nordisk A/S this week:

• Positive Sentiment: FDA approves Wegovy oral pill — a major commercial milestone that opens a new, non?injectable patient segment and supports a planned U.S. launch in early 2026. This is the key bullish catalyst many investors celebrated. Read More.
• Positive Sentiment: First?mover and efficacy edge vs. Lilly’s oral candidate — analysts note Novo may have a head start on oral GLP?1 market share and trial data show strong weight?loss results for oral Wegovy, which could help retention vs. competitors. Read More.
• Neutral Sentiment: Macro/ETF flow tailwinds — FDA nod to an oral GLP?1 is expected to lift healthcare and obesity?focused ETFs, bringing incremental investor demand even as company fundamentals are reassessed. Read More.
• Neutral Sentiment: Short?term market reaction volatility — coverage notes big share swings after the approval (both big pops and pullbacks) as investors reprice growth expectations for 2026. Read More.
• Negative Sentiment: Price cuts in China and margin pressure — Novo has cut Wegovy prices in some Chinese provinces and trimmed prices ahead of generic threats, which alongside broader pricing moves could compress margins. Read More. Read More.
• Negative Sentiment: Margins and investor impatience — commentary warns oral product economics and broader price competition could erode profitability; some analysts flag the risk that oral Wegovy and aggressive pricing will pressure margins and investor patience. Read More.
• Negative Sentiment: Intense competition from Eli Lilly — Lilly’s tirzepatide franchise and its oral candidate keep competitive pressure high; market share and pricing battles remain key downside risks. Read More. Read More.

Novo Nordisk A/S Stock Performance

Shares of NVO opened at $51.19 on Wednesday. The company has a quick ratio of 0.57, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. Novo Nordisk A/S has a 52-week low of $43.08 and a 52-week high of $93.80. The company has a 50-day simple moving average of $49.19 and a 200-day simple moving average of $56.21. The company has a market capitalization of $228.55 billion, a PE ratio of 14.88 and a beta of 0.67.

Novo Nordisk A/S (NYSE:NVO) last issued its earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share for the quarter, topping the consensus estimate of $0.77 by $0.25. Novo Nordisk A/S had a net margin of 32.76% and a return on equity of 73.50%. The company had revenue of $11.79 billion for the quarter, compared to analyst estimates of $11.98 billion. Equities research analysts predict that Novo Nordisk A/S will post 3.84 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on the company. Morgan Stanley reissued an “underweight” rating and issued a $42.00 target price on shares of Novo Nordisk A/S in a report on Wednesday, December 3rd. Weiss Ratings restated a “sell (d+)” rating on shares of Novo Nordisk A/S in a research report on Monday. Rothschild & Co Redburn raised shares of Novo Nordisk A/S from a “neutral” rating to a “buy” rating in a report on Tuesday, September 16th. Hsbc Global Res lowered shares of Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research note on Monday, November 24th. Finally, BMO Capital Markets restated a “market perform” rating on shares of Novo Nordisk A/S in a research report on Tuesday, December 23rd. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have assigned a Hold rating and four have assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, Novo Nordisk A/S presently has a consensus rating of “Hold” and a consensus target price of $53.33.

Novo Nordisk A/S Profile

Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.

The company’s core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.